Form 4: United Therapeutics Director Dwek Exercises Options and Sells Shares

Sentiment:

SEC Form 4


Director Raymond Dwek exercised stock options and sold shares of United Therapeutics Corp on April 14, 2025, according to a Form 4 filing.

Summary

  • Raymond Dwek, a director of United Therapeutics Corporation, executed transactions involving the company's stock on April 14, 2025.
  • Dwek exercised stock options to acquire 3,000 shares of common stock at a price of $175.43 per share.
  • Simultaneously, Dwek sold 3,000 shares of common stock at a price of $285.16 per share.
  • Following these transactions, Dwek directly owns 1,750 shares of United Therapeutics Corp.
  • The transactions were executed under a pre-arranged 10b5-1 trading plan established on August 2, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity under a pre-arranged plan.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives and directors to have pre-arranged trading plans like the 10b5-1 plan to avoid accusations of trading on inside information.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.

Key Dates

DateDescription
06/26/2016Original date the stock options became exercisable
08/02/2024Date the 10b5-1 trading plan was entered into
06/26/2025Expiration date of the stock options
04/14/2025Date of stock option exercise and share sale
04/15/2025Date of Form 4 filing

Keywords

Form 4, United Therapeutics, UTHR, stock options, insider trading, Raymond Dwek, 10b5-1 plan, share sale, director

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.